In order to identify the cells that can hypothetically benefit from the administration of EGFR-targeted therapies, we initially evaluated the mutational status of EGFR downstream pathways of 13 commercially available colon cancer cell lines, as well as a normal intestinal mucosa cell line. Here, EGFR is linked to malignant colon neoplasm.